Evidence map›Paper›PMID 32432393›Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2020

Going even smaller: Engineering sub-5 nm nanoparticles for improved delivery, biocompatibility, and functionality.

Manman Xie, Yaolin Xu, Jing Huang, Yuancheng Li, Liya Wang, Lily Yang, Hui Mao

Open access · greenAbstract readReview
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Strategies and mechanisms targetingFrontiers in cellular and infection microbiology · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022
    Review
  18. Article
  19. Review
  20. Rapid green-synthesis of TiORSC advances · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Manman XieDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.
Yaolin XuDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.
Jing HuangVascular Biology Program, Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Yuancheng LiDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.
Liya WangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.
Lily YangDepartment of Surgery, Emory University, Atlanta, Georgia, USA.
Hui MaoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-0147-6022
Emory University · USBoston Children's Hospital · US

Funding

Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer TherapyU01CA198913 · NCI · EMORY UNIVERSITY · PI MAO, HUI, YANG, LILY · 2015 to 2019
$3.0M
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticlesR01CA202846 · NCI · EMORY UNIVERSITY · PI MAO, HUI, WANG, YONGQIANG ANDREW · 2016 to 2020
$2.4M
Theranostic Nano particles for Targeted Treatment of Pancreatic CancerU01CA151810 · NCI · EMORY UNIVERSITY · PI MAO, HUI, YANG, LILY · 2010 to 2014
$2.2M
MRI Capable Receptor Targeted Drug Delivery for Pancreatic CancerR01CA154846 · NCI · EMORY UNIVERSITY · PI MAO, HUI, YANG, LILY · 2011 to 2015
$2.1M
NCI NIH HHS R01 CA154846NCI NIH HHS R01 CA202846NCI NIH HHS U01 CA151810NCI NIH HHS U01 CA198913NIH HHS 1U01CA19891301NIH HHS R01CA154846-04NIH HHS U01CA151810-05
6 · The paper itself

Abstract

The rapid development and advances in nanomaterials and nanotechnology in the past two decades have made profound impact in our approaches to individualized disease diagnosis and treatment. Nanomaterials, mostly in the range of 10-200 nm, developed for biomedical applications provide a wide range of platforms for building and engineering functionalized structures, devices, or systems to fulfill the specific diagnostic and therapeutic needs. Driven by achieving the ultimate goal of clinical translation, sub-5 nm nano-constructs, in particular inorganic nanoparticles such as gold, silver, silica, and iron oxide nanoparticles, have been developed in recent years to improve the biocompatibility, delivery and pharmacokinetics of imaging probes and drug delivery systems, as well as in vivo theranostic applications. The emerging studies have provided new findings that demonstrated the unique size-dependent physical properties, physiological behaviors and biological functions of the nanomaterials in the range of the sub-5 nm scale, including renal clearance, novel imaging contrast, and tissue distribution. This advanced review attempts to introduce the new strategies of rational design for engineering nanoparticles with the core sizes under 5 nm in consideration of the clinical and translational requirements. We will provide readers the update on recent discoveries of chemical, physical, and biological properties of some biocompatible sub-5 nm nanomaterials as well as their demonstrated imaging and theranostic applications, followed by sharing our perspectives on the future development of this class of nanomaterials. This article is categorized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Implantable Materials and Surgical Technologies > Nanomaterials and Implants.

Indexed as

NanoparticlesNanotechnologyGoldMagnetic Iron Oxide NanoparticlesSilicon DioxideSilverGoldSilicon DioxideSilverbiodistributionimagingnanoparticlesrenal clearancetheranostics

Identifiers

PMID32432393
PMCPMC8654183
OpenAlexW3027321689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.